✆ Contact Us ✉ info@icrazemagazine.com

Why personalised medicine is attracting record investment

Investment figures for personalised medicine are stacking up in ways that would have sounded implausible a decade ago. Specialist venture funds built around genomics and biomarker-led discovery have closed at record sizes, listed companies have reopened an IPO window for de-risked assets, and big pharma has been buying rather than building. Australian investors can feel the pull too — local biotech and diagnostics firms are being courted by overseas capital, and locally listed companies are drawing attention they haven't had since the last boom. What changed? Almost everything sitting upstream of a treatment decision got cheaper, faster and more precise at the same time.

Personalised medicine describes matching treatment to a person rather than an average: a drug chosen because a tumour carries a specific mutation, a dose adjusted for kidney function, an antibody therapy selected through a companion diagnostic. Pharmacogenomics extends the idea to the patient's own genetics, so a prescription that would once have caused side effects can be swapped out before it is written. In practice it depends on three things working together — a validated genomic test, an approved therapy tied to that test, and a health system willing to pay for both.

The timing is not a mystery. Sequencing costs fell far enough for hospitals to run panels on routine biopsies, machine learning made sense of messy biological datasets, and the immunotherapy wave of the late 2010s proved that targeting biology could produce durable responses in cancers that previously looked untouchable. The pandemic handed the field a manufacturing template through mRNA platforms, and GLP-1 medicines pushed attention toward obesity, insulin resistance and metabolic health, where tailoring by genotype and liver function is increasingly standard. Capital followed clinical results, and clinical results had followed capital.

What follows looks at where the money is moving, the regulatory and reimbursement realities that decide whether a breakthrough reaches a patient here at home, and the sceptics' case. The Australian angle matters more than usual: a national genomics push, faster PBS listing pathways and a research sector that punches above its weight all feed a global market chasing precision.

Record rounds and a reopened biotech market

Follow-on rounds are the clearest signal that investors no longer treat personalised medicine as a science project. Funds that launched with a single pipeline bet are now buying mature data, hiring commercial teams and selling secondary stakes at prices that make the next raise cheap. That reflexivity matters, because most discovery-stage medicines never survive their first clinical trial; a company with strong interim data can often raise without diluting shareholders or handing control to a bigger rival.

Pharmaceutical buying tells the same story from the other side. Instead of building internal biomarker platforms, large drugmakers have paid handsomely for validated tests, companion diagnostics and the data sets that connect them to a treatment. The market has learned that a therapy without a selection strategy is expensive, and a selection strategy without a therapy is worthless.

Why sequencing became cheap enough to matter

Ten years ago, profiling a tumour genome was a specialist request with a specialist invoice. Today a pathology lab can return a targeted panel for a handful of metastatic lesions, and liquid biopsy can pick up circulating tumour DNA from a blood draw when tissue is scarce. That price curve is what unlocked the investment case.

Alongside it came the software layer: machine learning that can read imaging, pathology and clinical records together, and biomarker discovery that runs across population-scale datasets rather than one small study. Investors are now underwriting pipeline shots where each candidate is pre-selected for the patients most likely to respond, which shortens trials and raises the odds of approval.

The approval and reimbursement pathway down under

Australia has a peculiar two-gate system, and investors studying the market learn it quickly. The Therapeutic Goods Administration assesses whether a medicine is safe and effective enough to sell, including whether any companion diagnostic must accompany it. The Pharmaceutical Benefits Advisory Committee then decides what the government will subsidise — and that second gate is where many global launches meet Australian reality.

Reform has been the theme. Faster listing pathways for innovative medicines have reduced the gap between a regulator's decision and a script being available at a local pharmacy, and Medicare item numbers cover a growing list of genetic tests performed on referral from a GP. Bulk-billing clinics and telehealth have widened access, particularly outside the capital cities.

Where the capital is landing in Australia

The research engine here is genuinely world class. The Walter and Eliza Hall Institute and Peter Mac in Melbourne, the Sanger Centre in Brisbane and the Hunter Medical Research Institute in Newcastle employ scientists who publish at the level of their American and European counterparts, and the talent pipeline is a draw for international teams setting up local operations.

Alongside them, a growing cohort of listed diagnostics and clinical-stage companies trades on the ASX, and AusBiotech events have become a place where global fund managers come to scout. It is no rare thing to hear an investor say they will "have a proper look in the arvo" — the sector's reputation for steady, unglamorous competence is now part of the pitch. Roadshow season means a lot of flying; we put together a guide to compact mirrorless cameras for travel for anyone covering it.

Diagnostics, direct-to-consumer tests and the wellness crowd

Retail-facing genetic testing has been the loudest consumer-facing story in the space, and Australia has not escaped it. Mail-order kits promise a personalised nutrition plan or a training profile for a modest price, and the marketing is sophisticated even where the evidence is thin. Pharmacists and chemists now stock an expanding range of over-the-counter health screens, and the line between a regulated diagnostic and a wellness product is a moving target.

That blur is where sceptics point, but it is also where the market is growing fastest. International health publishers covering consumer genomics and wellness science — Svetisava's health portal among them — see strong Australian traffic, because local media conversation about "optimising" health has been increasingly shaped by content that originated offshore.

Trial networks and the infrastructure behind the science

Money follows trials, and Australia is unusually good at running them. Public hospital networks, the ANZCTR registry and university research offices mean a trial can open in Adelaide and recruit nationally without a sponsor building everything from scratch. Contract research organisations have grown accordingly, and that infrastructure is now itself investable.

The bottleneck has shifted. Finding eligible patients takes longer than finding sites, which is why tumour-agnostic and biomarker-led designs are so attractive to sponsors: fewer patients, earlier signal, smaller trials. Investors are watching recruitment rates closely, because a trial that misses its enrolment window burns cash that could have funded the next molecule.

The sceptics, the risks and the privacy questions

The strongest objection is economic. Each additional diagnostic layer adds cost per patient, and health systems paying for precision can end up spending more overall if they also treat people a biomarker says they do not need treating. There is a real risk of over-diagnosis dressed up as personalisation, with healthy people referred into pathways that generate anxiety rather than benefit.

Equally, genomic data is unusually sensitive. A sequence reveals ancestry, biological relatives and predispositions that cannot be changed with a password reset, and Australian consumers have been burned before by how health data is handled. How publications and platforms collect and retain reader information is set out in our privacy policy.

The sensible reading is that precision will not replace standard medicine; it will sit on top of it, priced and prioritised carefully. Investors backing the sector are now being asked a harder question than "is the science real" — the answer is clearly yes. They are being asked who ends up paying, and whether the machinery built around these tests is as carefully governed as the molecules themselves.